Most people trust their own doctor most - as they should. This page gives your physician everything they need in one look.
To my doctor:
I'd like to be evaluated for esketamine (Spravato) treatment for depression that hasn't responded to the antidepressants I've tried. Could we talk about whether a referral makes sense - and if I don't meet criteria yet, which next medication trial would count toward them?
For the clinician
Indication: Spravato (esketamine CIII nasal spray) is FDA-approved for treatment-resistant depression in adults, as monotherapy or in conjunction with an oral antidepressant. It is also approved, in conjunction with an oral antidepressant, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Typical payer criteria: two or more adequate oral antidepressant trials in the current episode; concurrent oral antidepressant during treatment.
Administration: REMS program - administered only in certified healthcare settings with 2-hour post-dose observation; never dispensed for home use.
Our role: Brain Recovery Centers serves St. Charles County and St. Louis County, handles benefits verification and prior authorization, and returns outcome measures (PHQ-9, and PCL-5 where relevant) to you at the interval you prefer, with patient consent.
Referral & records: call (314) 314-9112 to coordinate; the patient can also self-refer via the screener at our site.
